Formulation and Evaluation of a Mucoadhesive Thermoresponsive System Containing Brazilian Green Propolis for the Treatment of Lesions Caused by Herpes Simplex Type I.

The aim of the present work was to develop a topical delivery system that contains Brazilian green propolis extract (PE-8) to increase efficiency and convenience when applied to herpetic lesions. The cytotoxicity and antiherpetic activity was determined in vitro and in vivo. The PE-8 was added to a system that contained poloxamer 407 and carbopol 934P.

Propolis Is an Efficient Fungicide and Inhibitor of Biofilm Production by Vaginal Candida albicans.

Vulvovaginal candidiasis (VVC) is one of the most common genital infections in women. The therapeutic arsenal remains restricted, and some alternatives to VVC treatment are being studied. The present study evaluated the influence of a propolis extractive solution (PES) on biofilm production by Candida albicans isolated from patients with VVC.

Microparticles containing propolis and metronidazole: in vitro characterization, release study and antimicrobial activity against periodontal pathogens.

Ethylcellulose microparticles containing metronidazole and propolis extractive solution were prepared and evaluated in vitro against periodontal pathogens. Scanning electron microscopy, particle size analysis, drug entrapment efficiency and drug release of microparticles were determined. The antimicrobial activity of microparticles was evaluated against microorganisms of periodontal importance (Enterococcus faecalis, Streptococcus pyogenes, Streptococcus mutans, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli).

Preparation and characterization of mucoadhesive thermoresponsive systems containing propolis for the treatment of vulvovaginal candidiasis.

This work describes the preparation and characterization of mucoadhesive thermoresponsive systems consisted of poloxamer 407 (P407), Carbopol® 934P (C934P), and propolis to treat vulvovaginal candidiasis (VVC). Systems were obtained with different percentages of P407 and C934P to deliver propolis, a potent drug against VVC. Temperature of gelation, hardness, compressibility, adhesiveness, elasticity, cohesiveness, mucoadhesion, rheology (continuous flow and oscillatory), in vitro drug release, and antimicrobial activity were evaluated.

Vaginal mucoadhesive drug delivery systems.

Background: The vaginal mucosal cavity is a feasible, safe, very attractive site for drug delivery and highly dynamic with respect to absorption of drugs, their metabolism and their elimination. Compared with other mucosal application sites, the vagina has the following advantages as, a fall in the incidence and severity of gastrointestinal side effects, avoidance of the inconvenience caused by pain, tissue damage and risk of infections which are associated with parenteral routes, ease of self-insertion and removal of the dosage form is possible. In addition, a prolonged contact of a delivery system with the vaginal mucosa may be achieved more easily than at other absorption sites like rectum or intestinal mucosa.